M. Preusser, R. Charles-Janzer, J. Felsberg, G. Reifenberger, M. F. Hamou, A. C. Diserens, R. Stupp, T. Gorlia, C. Marosi, H. Heinzl, J. A. Hainfellner, M. Hegi: Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. In: Brain Pathol. Band 18, Nr. 4, Okt 2008, S. 520–532. doi:10.1111/j.1750-3639.2008.00153.x.
G. Reifenberger, B. Malzkorn, T. Acker, M. Bettstetter, R. Buslei, A. von Deimling, W. Dietmaier, H. J. Dubbink, S. Eigenbrod, B. K. Garvalov, U. Gerstenmaier, A. Giese, D. Haase, M. Hasselblatt, E. Kirches, A. Koch, R. Marienfeld, M. Mittelbronn, M. Montesinos-Rongen, A. Pagenstecher, M. J. Riemenschneider, M. Prinz, B. Romeike, A. Roos, S. Spiegl-Kreinecker, J. Schittenhelm, J. Schlegel, D. R. Thal, B. B. Tops, J. Weis, G. Westphal, K. Worm, J. Felsberg: Results of the international interlaboratory comparison of mgmt promoter methylation analysis involving twenty-three academic centers in Germany, austria and the Netherlands. In: Neuro Oncol. Band 16, Suppl 3, Jul 2014, S. iii49–iii50. doi:10.1093/neuonc/nou209.30.
nih.gov
ncbi.nlm.nih.gov
Roger Stupp u. a.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. In: N Engl J Med. Band 352, 2005, S. 987–996. PMID 15758009.
Roger Stupp u. a.: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. In: Lancet Oncol. Band 10, Nr. 5, 2009, S. 459–466. PMID 19269895.
